CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Watters M

References:

Rank: 2 - Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.(Sep 2021)

Mutations:

Mutant	Gene	Virus	Reference
Y335H	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
Y335H	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
F342Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
F342Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V345I	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V345I	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
L348V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
L348V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
E362D	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
E362D	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V388M	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
V388M	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
H415Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
H415Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
A435V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
A435V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
C437Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
C437Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)

Tilloy et al., 2024

Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230